Decibel Therapeutics: Protect. Repair. Restore.
Emerging Company Profile: Decibel Therapeutics, a Boston-based company focused on developing therapies for hearing loss, started adding its voice in an emerging development space in 2015, with the aim of becoming "the premier hearing therapies company." With ongoing research and preclinical candidates for hearing loss, Decibel is looking to secure a beneficial collaboration that will bump up its profile and give it the funding it needs to move forward.
You may also be interested in...
Regeneron signed a unique agreement with the hearing-focused start-up Decibel in which it will make a minority equity investment and pay R&D costs, but leave full commercialization rights with its partner. The deal sprang from Regeneron’s outreach to venture-backed biotechs.
Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.
Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.